Rights and permissions
About this article
Cite this article
Infliximab beats adalimumab for moderate-to-severe UC. Pharmacoecon. Outcomes News 643, 9 (2011). https://doi.org/10.2165/00151234-201106430-00026
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-201106430-00026